Xention Ltd.

Xention Ltd is a leader in the discovery and development of ion channel modulating drugs. discovery and development. The Company has three potential breakthrough drugs in clinical development, XEND101, a new atrial selective potassium channel blocker for atrial fibrillation, and XEND401 and XEND501, novel ion channel modulators for the treatment of overactive bladder. Xention also has preclinical research programmes in pain and autoimmune disease. The Company uses proprietary expertise and technologies to accelerate the discovery of novel ion channel drugs, one of the largest class of pharmaceuticals. In particular, Xention is a leader in the use of true electrophysiological data, ion channel chemoinformatics and experienced medicinal chemistry to identify potent new small molecule drugs in this rapidly evolving field of medicine.